WHAT IS OZEMPIC® 2MG
Learn all about the new Ozempic® 2mg that's making headlines
Table of Contents
- What is Ozempic®?
- Can Ozempic® lower my risk for major cardiovascular events?
- How does Ozempic® work?
- The Calibrate difference: Taking Ozempic® as part of a metabolic reset program
- What does Ozempic® cost?
- Who is eligible for Ozempic®?
- Ozempic® side effects
- Ozempic® interactions & warnings
- Key Takeaways
- Frequently Asked Questions
Calibrate doctors prescribe a variety of GLP-1 medications, including semaglutide, liraglutide, and dulaglutide. Ozempic® (semaglutide) 2mg is a new medication Calibrate could offer.
What's the difference between Ozempic® and Ozempic® 2mg? We dig into this recently FDA-approved medication below.
Ozempic® 2 mg gets FDA approval in the U.S.
On March 28, 2022, the U.S. Food and Drug Administration (FDA) approved a new dose of the GLP-1 medication, Ozempic®: Ozempic® 2 mg, a higher dose of the once-weekly dosing of semaglutide subcutaneous injection, will now be available to patients in the U.S. Previously, only doses under 1.0 mg were offered.
The manufacturer of Ozempic®, Denmark-based Novo Nordisk, began working on its 2.0 mg dose of its semaglutide medication shortly after a 2019 clinical trial (the SUSTAIN FORTE trial) was published—a study that found that this increased dose better controlled blood sugar levels than doses of 1.0 mg.
According to a Novo Nordisk press release detailing the trial, “People treated with semaglutide 2 mg achieved a statistically significant and superior reduction in HbA1c at week 40 compared to semaglutide 1 mg dose. In the trial, both doses of semaglutide appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg.”
The 2 mg dose of Ozempic® was first approved for use in the EU in November 2021. Currently, the 2 mg dose of the medication is approved in the United States, Canada, EU, and Switzerland.
Get Started Today
Join thousands of members who have lost at least 10% of their body weight.
Will Ozempic® 2 mg dose be available for Calibrate members?
Ozempic® (semaglutide) is one of several GLP-1 (glucagon-like peptide-1) medications prescribed by Calibrate doctors to work in conjunction with the Calibrate One Year Metabolic Reset. Others include Wegovy®, Trulicity®, Rybelsus®, and Saxenda®.
Many factors are considered when prescribing a GLP-1. Your Calibrate doctor will take into account your unique needs, health history, and insurance coverage when deciding which GLP-1 medication, at which dosage, is right for you. Ozempic® 2.0 mg will become available to Calibrate members, should their doctor prescribe it, at the same time that it is available to the general public.
Have questions? Talk to your Calibrate doctor orcontact us to learn more.
What is Ozempic®?
Ozempic® (semaglutide) is a GLP-1 medication that’s FDA-approved for use in patients with type 2 diabetes. It is also used for the treatment of overweight and obesity and works by mimicking the incretin hormones that your body naturally produces when you eat food.
What are incretin hormones, then? Incretin hormones are gut hormone signals released by the small intestine whenever you consume food. These hormones travel throughout the body, signaling the brain, endocrine system, and gastrointestinal system that food has been consumed and is ready to be metabolized by the body for fuel. This results in a complex cascade of hormones and neurotransmitters that work together to communicate feelings of satiety (or feeling full).
Those with overweight or obesity may experience decreased production of natural incretin hormones—so a GLP-1 medication, like Ozempic®, helps the body make up the difference. Beyond their impact on satiety, GLP-1 medications also help regulate blood sugar levels.
Can Ozempic® lower my risk for major cardiovascular events? Very likely. In addition to improving blood sugar levels and A1C, preliminary data suggests that Ozempic® may lower the risk of major cardiovascular events such as heart attack, stroke, or death, particularly in adults with type 2 diabetes and known heart disease.
Ozempic® is a medication that makes it easier to lose body weight and stick to healthy habits. However, it doesn’t produce weight loss on its own: It must be used in combination with lifestyle changes in order to support overall metabolic health and avoid weight regain.
Calibrate’s One Year Metabolic Reset combines GLP-1 medication with evidence-based lifestyle recommendations—the Four Pillars of Metabolic Health—to help participants maximize their success with Ozempic®. These pillars include:
- Food
- Sleep
- Exercise
- Emotional health
Calibrate is a One-Year Metabolic Reset that uses proven methods for long-term results—the latest science, FDA-approved medication, 1:1 doctor visits, a structured curriculum, and accountability coaching on food, exercise, sleep, and emotional health—for weight loss of 10% or more. The Calibrate program was designed, vetted, and approved by a Clinical Advisory Board of world-renowned obesity experts.
When you join Calibrate, you’ll complete a Comprehensive Health Intake, including blood work, that your Calibrate doctor will carefully review before customizing your treatment plan and prescribing your medication. If your Calibrate medical team determines that Ozempic® is the right fit for you, they’ll walk you through all of the details on dosage, how to administer the medication, when to take it, and how it will work alongside your One-Year Metabolic Reset.
Keep in mind that Ozempic® is not the right fit for everyone. Calibrate doctors may prescribe other medications based on your unique needs and health insurance coverage.
Ozempic® 2 mg eligibility
All Calibrate members will be considered for Ozempic® as clinically appropriate and insurance eligible. Those with a history of any of the following conditions should talk to a doctor before starting Ozempic®:
- Endocrine tumors in the thyroid, parathyroid, pituitary, pancreas, or adrenal glands
- A family history of Multiple Endocrine Neoplasia type 2 (MEN2)
- Diabetes-related eye disease or vision problems
- Pancreatitis
- Active gallbladder disease
- Kidney disease
- Gastrointestinal issues
- Thyroid cancer or if someone in your family had thyroid cancer
- Pregnant, breast-feeding, or trying to get pregnant
- Heavy alcohol consumption
Key takeaways
Ozempic® (semaglutide) is a GLP-1 medication that, as of March 2022, is now approved in a 2.0 mg dose in addition to previously-offered 0.5 mg and 1.0 mg doses
- The FDA approved Ozempic® 2.0 mg in part thanks to data from a clinical trial that found that this increased dose better controlled blood sugar levels than the previous maximum dose of 1.0 mg
- Ozempic® is one of several GLP-1s prescribed by Calibrate doctors to members of the Calibrate program; the specific medication you are prescribed will depend on your unique health history and insurance coverage
While Ozempic® is indicated for use in patients with type-2 diabetes, its active ingredient, semaglutide, has been proven safe and effective for the treatment of overweight and obesity
IT’S ABOUT BIOLOGY
NOT WILLPOWER
Traditional weight loss programs don’t work because sustainable weight loss doesn’t come from yo-yo dieting or calorie counting. It comes from improving your metabolic health. Calibrate’s One-Year Metabolic Reset helps you do just that, through a unique combination of doctor-prescribed medication, 1:1 video coaching, and lifestyle tweaks tailored to you. The result? Improved metabolic health and sustained weight loss.
Donya's Story
Frequently Asked Questions
Footnotes
- -†https://www.ozempic.com/why-ozempic/what-is-ozempic.html
- -†https://www.ozempic.com/why-ozempic/what-is-ozempic.html
- -†https://clinicaltrials.gov/ct2/show/NCT03574597
- -†https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690432/
- -†https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
- -†https://www.drugs.com/price-guide/ozempic
- -†https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf